Standards of Medical Care in Diabetes to inform clinicians on components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. In the 2018 Standards, recommendations related to the use of antihyperglycemic therapy in adults with type 2 diabetes were updated in consideration of new evidence published since the last iteration in 2017. This brief review summarizes key recommendations from the 2018 Standards related to the pharmacologic management of people with type 2 diabetes. In so doing, it additionally highlights drug-and patient-specific factors to consider when intensifying antihyperglycemic therapy.
A ccording to estimates from the Centers for Disease Control and Prevention, 30.3 million people in the United States currently live with diabetes (1) . For people living with diabetes, optimization of glycemic control is one of several key treatment approaches central to avoiding or delaying the microvascular and macrovascular complications of the disease. Although lifestyle interventions are integral to any diabetes management plan, this brief review will focus on current recommendations from the American Diabetes Association's (ADA's) Standards of Medical Care in Diabetes-2018 (Standards) for the use of antihyperglycemic therapies in the management of people with type 2 diabetes. Table 1 provides a summary of general glycemic recommendations for non-pregnant adults with diabetes (2) . It should be noted that, although general recommendations for A1C, preprandial glucose, and postprandial glucose levels are provided, all glycemic goals should be individualized based on person-specific considerations (2) . Factors that may inform glycemic goals for an individual may include risk of hypoglycemia and other adverse drug events, type 2 diabetes disease duration, life expectancy, comorbidity burden, presence of vascular complications, attitudes and treatment expectations of the individual, and resources and support available to implement a given treatment plan (2, 3) . Ultimately, the n e u m i l l e r a n d u m p i e r r e z
Glycemic Goal Setting

F R O M R E S E A R C H T O P R A C T I C E
ADA recommends that treatment decisions should be made and glycemic goal-setting should occur in collaboration with individual patients whenever possible to incorporate their needs, preferences, and values (2).
Initial Antihyperglycemic Therapy
At the time of a diagnosis of type 2 diabetes, the ADA recommends prompt initiation of lifestyle management, determination of appropriate glycemic targets (inclusive of A1C goals), and initiation of pharmacologic therapy (2) . Figure 1 provides (4, 5) . Both currently approved products (insulin degludec/liraglutide and insulin glargine/ lixisenatide) are indicated for use in patients who are already receiving one of the agents contained within the fixed-dose combination product (i.e., the insulin degludec/liraglutide product is indicated in people inadequately controlled on basal insulin or liraglutide) (4, 5) .
Focusing on situations in which monotherapy is indicated, metformin is recommended as the preferred firstline therapy at the time of diagnosis provided there are no contraindications for its use (such as an estimated glomerular filtration rate [eGFR] <30 ml/min/1.73 m 2 ) (2). Metformin is preferred as a first-line agent because of its demonstrated efficacy, safety, low cost, and possible benefits in reducing the risks of cardiovascular events and death (6, 7) . For patients with a contraindication to or significant intolerance of metformin, initial monotherapy can begin with an agent from another medication class, with the choice of agent determined based on the specific needs and preferences of the individual. Table 2 Figure 1 , A1C should be measured 3 months after initiation of monotherapy (2) . If the individualized A1C goal is not achieved after 3 months of consistent monotherapy, combination therapy should be considered.
Combination Therapy
For individuals requiring dual combination therapy to meet individualized glycemic goals, the agent(s) recommended for add-on to metformin are stratified based on the presence or absence of atherosclerotic cardiovascular disease (ASCVD) (2) . For people without ASCVD, the ADA recommends considering a combination of metformin plus another agent from one of the following preferred medication classes: sulfonylurea, thiazolidinedione, dipeptidyl peptidase 4 (DPP-4) inhibitor, sodium-glucose cotransporter 2 (SGLT2) inhibitor, GLP-1 receptor agonist, or basal insulin (2) . The choice of which agent to use in combination with metformin should be based on drug-and person-specific considerations. For those with ASCVD, however, the ADA recommends a combination of metformin with an agent proven to reduce major adverse cardiovascular events (MACE) and/or cardiovascular mortality (2) . Based on current evidence, the ADA recommends the consideration of liraglutide, empagliflozin, or canagliflozin in such individuals (2) . The 2018 Standards include the following specific recommendations for the selection of an agent for add-on to metformin in those requiring additional glucose lowering (2, (8) (9) (10) .
• In patients without ASCVD, if monotherapy or dual therapy does not achieve or maintain the A1C goal over 3 months, add an additional antihyperglycemic agent based on drug-specific and patient factors. A
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■ FIGURE 1. Antihyperglycemic therapy in adults with type 2 diabetes. *If patient does not tolerate or has contraindications to metformin, consider agents from another class in • In patients with type 2 diabetes and established ASCVD, antihyperglycemic therapy should begin with lifestyle management and metformin and subsequently incorporate an agent proven to reduce MACE and cardiovascular mortality (currently empagliflozin and liraglutide), after considering drug-specific and patient factors. A • In patients with type 2 diabetes and established ASCVD, after lifestyle management and metformin, the antihyperglycemic agent canagliflozin may be considered to reduce MACE, based on drug-specific and patient factors. C All three of the recommendations highlighted above make note of the importance of drug-specific and patient factors when selecting an appropriate therapy as add-on to metformin. Factors outlined in Table 2 can be considered when selecting an agent in a given individual (2) . Beyond factors such as efficacy, hypoglycemia risk, weight effects, cost, and route of administration, recently published data have highlighted the additional benefits of GLP-1 receptor agonists and SGLT2 inhibitors on cardiovascular and renal outcomes (8) (9) (10) . For example, in dedicated cardiovascular outcome trials with empagliflozin, liraglutide, and canagliflozin, all were shown to slow the progression of nephropathy, with empagliflozin and canagliflozin showing benefit in preventing hospitalization for heart failure (8-10). Such considerations may drive the use of these agents in a given individual based on the presence of key comorbidities.
Similar to the decision-making process discussed above for transitioning from monotherapy to dual therapy in those not achiev-■ FIGURE 2. Combination injectable therapy for type 2 diabetes. hypo, hypoglycemia; SMBG, self-monitoring of blood glucose. Reprinted with permission from the American Diabetes Association (2).
ing or maintaining glycemic goals, triple combination therapy is recommended for those not achieving or maintaining treatment goals with dual therapy alone (2) . If triple therapy is proven insufficient to meet glycemic goals, consideration of combination injectable therapy is recommended. Figure 2 provides recommendations for the implementation of combination injectable therapy in people with type 2 diabetes (2). The figure, starting at the top, provides some guidance on the initiation and titration of basal insulin, inclusive of a recommended starting dose (10 units/day or 0.1-0.2 units/kg/day) and guidance on titration of the basal insulin to achieve an individualized fasting blood glucose (FBG) target (2) . If goal A1C is not met following basal insulin optimization and achieving the target FBG, the addition of injectable agents targeting postprandial glucose excursions is recommended. For this scenario, Figure 2 outlines three recommended combination injectable approaches after basal insulin optimization: 1) the addition of one rapid-acting insulin injection with the largest meal, 2) the addition of a GLP-1 receptor agonist, or 3) transition to a premixed insulin product administered twice daily (2) . Although basal insulin in combination with a GLP-1 receptor agonist is associated with less hypoglycemia and the potential for weight loss instead of weight gain when compared to a basal-bolus insulin approach (11, 12) , these potential benefits must be weighed against the potential for gastrointestinal intolerance and the cost of treatment. It should be noted that if one of these approaches proves to be ineffective or is otherwise not tolerated, changing to an alternative approach might be appropriate.
Combination Injectable Therapy
Moving downward in Figure  2 , if initial combination injectable 
